FIA
GLMD icon

FNY Investment Advisers’s Galmed Pharmaceuticals GLMD Stock Holding History

FNY Investment Advisers’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-156
Closed -$333K – 1040
2018
Q2 		$333K Buy
+156
New +$226K 0.13% 109

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's GLMD Position: Q3 2018 in Review

FNY Investment Advisers sold out of Galmed Pharmaceuticals (GLMD) in Q3 2018, closing a stake of 156 shares — an estimated $333K sold.

FNY Investment Advisers first reported a position in GLMD in Q2 2018 and held it in 1 quarter. The position peaked at $333K in Q2 2018. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

  • FNY Investment Advisers reported no remaining Galmed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 156 Galmed Pharmaceuticals shares in Q3 2018, an estimated $333K.
  • FNY Investment Advisers first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Galmed Pharmaceuticals position peaked at $333K in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on FNY Investment Advisers's 13F filing for Q3 2018, filed 29 Oct 2018.